JW THERAP-B (02126) announced that Mr. Tian Feng will be appointed as the company's Chief Executive Officer and Executive Director, effective December 29, 2025. Dr. Liu Cheng has been appointed as Chairman of the Board, effective December 12, 2025.

The Board further announced that Mr. Liu Min, the current Executive Director, Chairman, and CEO, has resigned from all positions—including membership on the Nomination Committee and Business Development & Strategy Committee—due to personal career development, effective December 12, 2025.

Following Mr. Tian's appointment and Mr. Liu Min's resignation, the Board confirmed that Mr. Tian will join the Nomination Committee and Business Development & Strategy Committee, effective December 29, 2025.

Additionally, Dr. Liu Cheng will replace Mr. Liu Min as the company's authorized representative under Rule 3.05 of the Listing Rules, effective December 12, 2025. After these changes, the authorized representatives will be Dr. Liu Cheng and the Company Secretary, Ms. Wu Jiawen.

From December 29, 2025, Mr. Tian will replace Dr. Liu Cheng as an authorized representative, making the authorized representatives Mr. Tian and Ms. Wu.

In other developments, on September 16, 2025, the Board approved a proposal to grant Mr. Liu Min 4,204,500 share options under the post-IPO incentive plan, subject to shareholder approval (the "September 2025 Grant"). However, due to the delayed dispatch of related documents and the fact that Mr. Liu Min's resignation took effect before the extraordinary general meeting, the Board has decided to cancel the September 2025 Grant effective December 12, 2025. The cancellation was agreed upon by Mr. Liu Min.